Targeted Liposomes With C-Type Lectin for Pathogen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating infectious diseases, particularly fungal, viral, and bacterial infections, are deficient in efficacy and specificity.
Innovation Solution
Development of targeted nanoparticles, specifically liposomes, incorporating a C-Type Lectin polypeptide or its fragment with a carbohydrate recognition domain (CRD) on the surface to bind pathogen antigens, optionally encapsulating antipathogenic agents like antiviral, antifungal, or antibacterial drugs, enhancing targeting and reducing toxicity to animal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic and treatment methods are used for infectious diseases, then treatment can be provided, but efficacy and specificity are deficient
Solution Approach 1:
The patent modifies the physical and chemical parameters of drug delivery by using liposomal encapsulation with surface-modified C-type lectin polypeptides. This changes the targeting mechanism from non-specific to antigen-specific binding, thereby improving efficacy without substantially increasing operational complexity
Solution Approach 2:
The C-type lectin polypeptide acts as an intermediary between the liposome carrier and the pathogen antigen. This mediator enables specific recognition and binding to the target pathogen, enhancing both efficacy and specificity of the treatment approach
2Reliability
If higher drug concentrations are used to improve treatment efficacy, then pathogen killing increases, but toxicity to animal cells increases
Solution Approach 1:
The liposome delivers the antipathogenic agent directly to the local site of infection by binding to pathogen-specific antigens. This localized delivery concentrates the drug effect at the target site while minimizing exposure and toxicity to healthy animal cells
Solution Approach 2:
The C-type lectin polypeptide serves as a targeting intermediary that directs the drug-carrying liposome to the pathogen. This enables selective drug delivery, allowing effective concentrations at the target while maintaining lower overall drug levels that reduce systemic toxicity
3Ease of operation
If non-specific treatment methods are used, then treatment can be administered, but specificity to pathogen targets is low
Solution Approach 1:
The patent introduces antigen-specific C-type lectin polypeptides on the liposome surface, changing the binding parameter from non-specific to specific antigen-antibody-like recognition. This enhances targeting precision while maintaining relatively simple administration procedures
Solution Approach 2:
The treatment system is segmented into distinct functional components: the liposome carrier, the C-type lectin targeting moiety, and the encapsulated antipathogenic agent. This segmentation allows the targeting function to be independently optimized while keeping the overall administration process manageable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liposomes demonstrate enhanced binding to pathogenic cells, reducing drug concentration requirements and toxicity, and effectively treating or preventing infections by sequestering pathogens or delivering drugs directly to the target site.
Implementation Method 1
a C-Type Lectin polypeptide or a fragment thereof comprising a carbohydrate recognition domain (CRD), wherein the targeting molecule is incorporated into the outer surface of the liposome
Data Source
AI summary
Infectious diseases continue to burden populations around the world. Both naturally occurring and engineered biological threats hold increasing potential to cause disease, disability, and death. The liposomes comprise a targeting molecule that binds a target antigen expressed by a pathogen, wherein the targeting molecule is a C-Type Lectin polypeptide or a fragment thereof comprising a carbohydrate recognition domain (CRD), wherein the targeting molecule is incorporated into the outer surface of the liposome. Provided herein are targeted nanoparticle compositions and methods for the diagnosis, treatment or prevention of an infectious disease using same.